Gelonghui, May 8 | Jingxin Pharmaceutical (002020.SZ) said on the investor interactive platform that Shaxi Pharmaceutical is unable to carry out effective renovation and expansion because the site and plant are not independent property rights. The company has built a new production base for traditional Chinese medicine in Beijing, Inner Mongolia, and trial production began in October last year. Currently, production of some varieties of Shaxi Pharmaceutical is being transferred in an orderly manner to new production areas in Inner Mongolia.
京新药业(002020.SZ)：目前沙溪制药部分品种的生产正有序地向内蒙新产区转移
Jingxin Pharmaceutical (002020.SZ): Currently, production of some varieties of Shaxi Pharmaceutical is being transferred in an orderly manner to the new production area in Inner Mongolia
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.